| __timestamp | Soleno Therapeutics, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2917513 | 5078000000 |
| Thursday, January 1, 2015 | 7878291 | 4717000000 |
| Friday, January 1, 2016 | 8366794 | 5096000000 |
| Sunday, January 1, 2017 | 6610381 | 4986000000 |
| Monday, January 1, 2018 | 6556000 | 4214000000 |
| Tuesday, January 1, 2019 | 6930000 | 3806000000 |
| Wednesday, January 1, 2020 | 8758000 | 3671000000 |
| Friday, January 1, 2021 | 10806000 | 3528000000 |
| Saturday, January 1, 2022 | 9844000 | 3445000000 |
| Sunday, January 1, 2023 | 13481000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Teva Pharmaceutical Industries Limited and Soleno Therapeutics, Inc., from 2014 to 2023.
Teva, a global leader, consistently reported SG&A expenses in the billions, peaking in 2016. However, a notable decline of approximately 32% was observed by 2023, reflecting strategic cost management. In contrast, Soleno, a smaller entity, exhibited a steady increase in SG&A expenses, growing by nearly 362% over the same period. This trend underscores Soleno's aggressive expansion and investment in operational capabilities.
Understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning, providing a window into the broader pharmaceutical landscape.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Soleno Therapeutics, Inc.
Summit Therapeutics Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Jazz Pharmaceuticals plc and Soleno Therapeutics, Inc.
Comparing SG&A Expenses: Lantheus Holdings, Inc. vs Soleno Therapeutics, Inc. Trends and Insights
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Merus N.V. vs Soleno Therapeutics, Inc.: SG&A Expense Trends